- Acadia Pharmaceuticals buys startup drugmaker for $52M
San Diego-based Acadia Pharmaceuticals has agreed to purchase CerSci, a Dallas-based startup drugmaker for $52 million to acquire a pain drug CerSci has been developing. If the drug succeeds, CerSci may receive up to an additional $887 in payments, according to a news release. - Bristol Myers Squibb agrees to buy cancer drugmaker for undisclosed sum
Bristol Myers Squibb has agreed to buy Forbius, a drugmaker that focuses on cancer and fibrotic diseases, for an undisclosed sum. Bristol Myers Squibb said the transaction includes an upfront payment and future success-based milestone payments. - Takeda to sell OTC drug business to US private equity firm for $2.37B
Japan-based Takeda Pharmaceutical has agreed to sell its over-the-counter drug business to Blackstone Group, a U.S. private equity firm, for $2.37 billion. - J&J to acquire Momenta Pharma for $6.5B
Johnson & Johnson has agreed to buy Cambridge, Mass.-based Momenta Pharmaceuticals for $6.5 billion, a move to strengthen the drugmaker’s portfolio of autoimmune disease treatments. - Gilead extends oncology partnership with Tango Therapeutics, scales deal up to $6B
Gilead has expanded its contract with Tango Therapeutics, seeking to further pursue the collaborative development and commercialization of immuno-oncology treatments. Gilead will pay $125 million up front, as well as a $20 million equity investment. It can opt in to up to 15 programs over the seven-year period, paying Tango up to $410 million per program. - Sanofi inks $3.68B deal to buy California autoimmune drugmaker
Sanofi has agreed to buy South San Francisco, Calif.-based Principia Biopharma for $3.68 billion. - Biogen inks $1B+ deal with Denali for Parkinson’s treatment
Cambridge, Mass.-based drugmaker Biogen has struck a more than $1 billion deal with South San Francisco-based biotech company Denali to co-develop and co-commercialize small molecule inhibitors to treat Parkinson’s disease. - AstraZeneca to pay Emergent $174M to expand production of COVID-19 vaccine candidate
Gaithersburg, Md.-based drugmaker Emergent BioSolutions has signed a $174 million deal with AstraZeneca, agreeing to scale up manufacturing for the British pharma giant’s COVID-19 vaccine candidate. - AstraZeneca, Daiichi Sankyo partner in $6B cancer drug deal
British drugmaker AstraZeneca has signed a deal with Japanese drugmaker Daiichi Sankyo to develop an oncology drug with fewer side effects than traditional cancer treatments. Under the agreement, AstraZeneca will pay Daiichi Sankyo $1 billion up front, another $1 billion after the drug gains regulatory approval, and up to $4 billion for future sales. - Gilead deal gives it option to buy California drugmaker for $1.25B
Gilead plans to invest $300 million to acquire a 49.9 percent stake in Brisbane, Calif.-based Tizona Therapeutics and has signed a deal giving it the option to acquire the rest of the drugmaker for an additional $1.25 billion. - GlaxoSmithKline invests $164M in 5 CureVac vaccines
GlaxoSmithKline has acquired a 10 percent stake in German biotech company CureVac for $163.67 million. The deal focuses on developing five mRNA-based vaccines and monoclonal antibodies to prevent and treat infectious diseases.
More articles on pharmacy:
Patients over 50 may take meds less if pill appearance changes a lot, study says
U.S. cities with the highest, lowest prescription drug costs
US sues Teva for 2nd time in 1 week, this time for alleged price-fixing scheme
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.